Literature DB >> 19152000

Clinical practice treatment of HIV infection in children.

Bénédicte Brichard1, Dimitri Van der Linden.   

Abstract

Perinatal transmission remains the main cause of HIV infection in the pediatric population. Treatment of HIV-infected children has become less of a problem in resource-rich countries with a remarkable decrease of perinatal infections, resulting in an effective prevention of mother-to-child transmission and antiretroviral treatment of HIV infection in pediatrics because of differences in drug pharmacokinetics, the lack of available licensed drugs, the use of different immunologic markers and age-related adherence issues. This review, for the general pediatrician, summarizes the most recent pediatric data and guidelines for treatment of HIV. Recommendations for when to initiate therapy are more aggressive in children than in adults, particularly in infants because disease progression in children is more rapid. The indications to start therapy differ by age and are based on international immunologic and clinical classification system for HIV infection. At present, combination regimens of at least three drugs are recommended. Moreover, therapies must also consider the potential complications in these children currently treated for a long time.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19152000     DOI: 10.1007/s00431-008-0914-8

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  26 in total

Review 1.  Pediatric HIV infection: diagnostic laboratory methods.

Authors:  Jorge Lujan-Zilbermann; Carina A Rodriguez; Patricia J Emmanuel
Journal:  Fetal Pediatr Pathol       Date:  2006 Sep-Oct       Impact factor: 0.958

2.  Efavirenz liquid formulation in human immunodeficiency virus-infected children.

Authors:  Stuart E Starr; Courtney V Fletcher; Stephen A Spector; Richard C Brundage; Florence H Yong; Steven D Douglas; Patricia M Flynn; Mark W Kline
Journal:  Pediatr Infect Dis J       Date:  2002-07       Impact factor: 2.129

Review 3.  International recommendations on antiretroviral drugs for treatment of HIV-infected women and prevention of mother-to-child HIV transmission in resource-limited settings: 2006 update.

Authors:  Halima Dao; Lynne M Mofenson; Rene Ekpini; Charles F Gilks; Matthew Barnhart; Omotayo Bolu; Nathan Shaffer
Journal:  Am J Obstet Gynecol       Date:  2007-09       Impact factor: 8.661

4.  Antiretroviral therapy, fat redistribution and hyperlipidaemia in HIV-infected children in Europe.

Authors: 
Journal:  AIDS       Date:  2004-07-02       Impact factor: 4.177

Review 5.  Novel treatment options for pediatric HIV infection.

Authors:  Eleanor Day; Karen Buckberry; Michael R Sharland; Rana Chakraborty
Journal:  Curr Opin Investig Drugs       Date:  2008-02

Review 6.  Nucleoside and nucleotide reverse transcriptase inhibitors in children.

Authors:  Carlo Giaquinto; Osvalda Rampon; Martina Penazzato; Federica Fregonese; Anita De Rossi; Ruggiero D'Elia
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

7.  Effectiveness of early initiation of protease inhibitor-sparing antiretroviral regimen in human immunodeficiency virus-1 vertically infected infants.

Authors:  Dimitri Van der Linden; Marc Hainaut; Tessa Goetghebuer; Edwige Haelterman; Véronique Schmitz; Philip Maes; Alexandra Peltier; Jack Levy
Journal:  Pediatr Infect Dis J       Date:  2007-04       Impact factor: 2.129

8.  Early antiretroviral therapy and mortality among HIV-infected infants.

Authors:  Avy Violari; Mark F Cotton; Diana M Gibb; Abdel G Babiker; Jan Steyn; Shabir A Madhi; Patrick Jean-Philippe; James A McIntyre
Journal:  N Engl J Med       Date:  2008-11-20       Impact factor: 91.245

9.  Lamivudine/abacavir maintains virological superiority over zidovudine/lamivudine and zidovudine/abacavir beyond 5 years in children.

Authors:  H Green; D M Gibb; A S Walker; D Pillay; K Butler; F Candeias; G Castelli-Gattinara; A Compagnucci; M Della Negra; A de Rossi; C Feiterna-Sperling; C Giaquinto; L Harper; J Levy; Y Saidi; U Wintergerst
Journal:  AIDS       Date:  2007-05-11       Impact factor: 4.177

Review 10.  International perspectives, progress, and future challenges of paediatric HIV infection.

Authors:  Andrew Prendergast; Gareth Tudor-Williams; Prakash Jeena; Sandra Burchett; Philip Goulder
Journal:  Lancet       Date:  2007-07-07       Impact factor: 79.321

View more
  3 in total

1.  Relative Bioavailability of a Dolutegravir Dispersible Tablet and the Effects of Low- and High-Mineral-Content Water on the Tablet in Healthy Adults.

Authors:  Ann M Buchanan; Michael Holton; Ian Conn; Mark Davies; Mike Choukour; Brian R Wynne
Journal:  Clin Pharmacol Drug Dev       Date:  2017-02-07

2.  Time to treatment disruption in children with HIV-1 randomized to initial antiretroviral therapy with protease inhibitors versus non-nucleoside reverse transcriptase inhibitors.

Authors:  Dwight E Yin; Christina Ludema; Stephen R Cole; Carol E Golin; William C Miller; Meredith G Warshaw; Ross E McKinney
Journal:  PLoS One       Date:  2020-11-23       Impact factor: 3.240

3.  Pharmacotherapy of pediatric and adolescent HIV infection.

Authors:  Susan J Schuval
Journal:  Ther Clin Risk Manag       Date:  2009-06-22       Impact factor: 2.423

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.